Translational Software releases new white paper "A Lab Leader's Guide to Pharmacogenomic Testing (PGx)" at International Molecular Medicine Tri-Conference

February 17, 2015

Focus on current and future role of pharmacogenomic testing; cloud-based software offers practical and cost-effective tool for clinicians

SAN FRANCISCO, CA - Feb 17, 2015 -  

Translational Software, Inc., a leader in integrating genetic information into routine clinical care, has announced the release of a new white paper, “A Lab Leader’s Guide to Pharmacogenomic Testing (PGx).”  It focuses on the current and future role of PGx testing to drive improved patient care, and the use of cloud-based software in making PGx testing a practical and cost-effective tool for clinicians.

The release coincides with Translational Software’s participation (booth #103) at the International Molecular Medicine Tri-Conference, this week at Moscone North Convention Center in San Francisco.

Prepared in conjunction with the Dark Report, the paper focuses on the current challenges of pharmacogenomics testing, practical solutions to overcoming obstacles, and its ultimate role as a tool in decreasing medical costs.

It is available for downloading, at no charge, by visiting the Dark Report.

“Analyzing the complex information involved in PGx testing, and comparing it to the drugs the patient is being prescribed, holds challenges for busy physicians,” said Don Rule, Translational Software’s founder and CEO. “Providing actionable, easy to understand intelligence is critical to expanding PGx testing, with the ultimate goal of driving good medical care in a cost-effective, efficient and reliable manner.”

Specific elements of the white paper include:

·Benefits of pharmacogenomics testing

·studies supporting the clinical usefulness of PGx testing

·barriers to entry into the pharmacogenomic testing market

·outsourcing analytical support to make  PGx testing a viable option for laboratories

·advantages to a service that specializes in PGx interpretation

·current status of genomic testing in the lab market, and what the future may hold

Translational Software  provides end-to-end solutions to support physicians adopting personalized medicine. Its powerful PGx Portal (PGxP) is an advanced, cloud-based solution providing clients with access to company’s proprietary knowledgebase. Coupled with advanced laboratory molecular data, it generates HIPAA-compliant reports for referring clinicians with easy-to-understand recommendations and guidance on therapeutic options for patients’ medication management.

The reports are targeted to clinical specialties, and can be integrated with existing Laboratory Information Systems (LIS) to significantly reduce costs and turnaround time.

For more information visit www.translationalsoftware.com

 

                                                                        # # #

Media Contacts:

Barry Bartlett, The Bartlett Group, 206-335-4694 (m), or barry@bartlettgrouppr.com

Rick Shigaki, V.P. Sales/Marketing, Translational Software

206-777-4396 (office), or rick.shigaki@translationalsoftware.com